Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
293 hedge funds and large institutions have $3.31B invested in Amicus Therapeutics in 2024 Q3 according to their latest regulatory filings, with 59 funds opening new positions, 91 increasing their positions, 93 reducing their positions, and 24 closing their positions.
146% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 24
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
14% more funds holding
Funds holding: 258 → 293 (+35)
6% more capital invested
Capital invested by funds: $3.13B → $3.31B (+$184M)
2% less repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 93
1.89% less ownership
Funds ownership: 106.42% → 104.53% (-1.9%)
29% less call options, than puts
Call options by funds: $6.37M | Put options by funds: $8.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$31.1M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
+$28.1M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$19M |
| 4 |
BlackRock
New York
|
+$18.9M |
| 5 |
Goldman Sachs
New York
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
-$75.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$46M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$28.2M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$25.6M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$24.6M |
FOLD Hedge Fund Activity: Q3 2024 in Review
293 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q3 2024, worth a combined $3.31B — up 5.9% from $3.13B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new FOLD positions and 24 closed out — a net gain of 35 holders — while 91 added to existing stakes and 93 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $31.1M. The largest seller was Janus Henderson Group, cutting an estimated $75.1M.
- 293 institutional investors held Amicus Therapeutics (FOLD) as of Q3 2024, up from 258 in Q2 2024.
- Funds reported $3.31B of Amicus Therapeutics stock for Q3 2024, up 5.9% quarter-over-quarter.
- 59 funds opened new Amicus Therapeutics positions in Q3 2024 and 24 closed out, a net change of +35 holders.
- The largest Amicus Therapeutics buyer in Q3 2024 was Wellington Management Group, an estimated $31.1M added.
- The largest Amicus Therapeutics seller in Q3 2024 was Janus Henderson Group, an estimated $75.1M sold.
Based on aggregated 13F filings for Q3 2024.